

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/852,408 05/09/2001		05/09/2001	Carlos Schuler	015225-005910US	5388
21968	7590	12/02/2004		EXAMINER	
NEKTAR '	THERAP	EUTICS	PATEL, NIHIR B		
150 INDUS	TRIAL RO)AD			
SAN CARL	OS, CA	94070	ART UNIT	PAPER NUMBER	
	•			3743	

DATE MAILED: 12/02/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

|--|

	Application No.	Applicant(s)					
	09/852,408	SCHULER ET AL.					
Office Action Summary	Examiner	Art Unit					
	Nihir Patel	3743					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
Responsive to communication(s) filed on 2a) ☑ This action is FINAL.							
Disposition of Claims							
4) ☐ Claim(s) is/are pending in the application 4a) Of the above claim(s) is/are withdray 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-9, 11-22, 24-32, 34-36 is/are rejected 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	wn from consideration.						
Application Papers							
 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. 							
Priority under 35 U.S.C. § 119							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
Attachment(s)	_						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:						

Application/Control Number: 09/852,408

Art Unit: 3743

DETAILED ACTION

Response to Arguments

Applicant's arguments filed on October 1st, 2004 have been fully considered but they are not persuasive. In reference to claims 1, 17, and 28, the applicant argues that Goodman does not disclose an aerosol generator for aerosolizing the drug formulation in response to manual actuation. The examiner disagrees. Goodman dos disclose an aerosol generator for aerosolizing the drug formulation in response to manual actuation (see column 1 lines 10-30).

In conclusion claims 1-9, 11, 15-22, 24, 25, and 28-32 are rejected under 35 USC 102(b) as being anticipated by US Patent No. 5,404,871 to Goodman et al. and claims 12-14, 26, 27, and 34-36 under 35 USC 103(a) as being unpatentable over Goodman et al. in view of PCT WO/94/16759 to Ritson et al as stated in the previous office action dating back to Mach 12th, 2004

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the

Application/Control Number: 09/852,408

Page 3

Art Unit: 3743

advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communication from the examiner should be directed to Nihir Patel whose telephone number is (571) 272-4803. The examiner can normally be reached on Monday-Friday from 7:30 am to 4:30 pm. If attempts to reach the examiner by telephone are unsuccessful the examiner supervisor Henry Bennett can be reached at (571) 272 4791.

NP November 29th, 2004

Henry Bennett
Supervisory Patent Examiner